Contribute Try STAT+ Today

A second U.S. government agency is now reviewing whether Moderna (MRNA) properly disclosed millions of dollars in federally funded awards in several patents and patent applications the company filed for its vaccines.

The Biomedical Advanced Research and Development Authority is reviewing contracts awarded to the vaccine maker in response to a request from an advocacy group that analyzed dozens of patent applications. To date, BARDA has awarded the company up to $955 million to develop a vaccine based on its mRNA technology that would be jointly invented by the National Institutes of Health.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.